Vilka är öppettiderna?

Måndag 08:00 - 17:00 Tisdag 08:00 - 17:00 Onsdag 08:00 - 17:00 Torsdag 08:00 - 17:00 Fredag 08:00 - 17:00

Alzecure

Hem
Sverige
Huddinge
Alzecure

Ring Vägbeskrivning Webbplats Kontakta praktiken

Alzecure is a non-profit research foundation with funding initially from donations and grants from individuals, non-profit organizations and governments.

AlzeCure develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer’s disease and pain – indications for which currently available treatment is very limited. The objective of Alzecure Foundation is to enhance scientific research in age related diseases, primarily Alzheimer’s disease and other neurodegenerative conditions, with the aim to develop new therapies, diagnostics, treatments and medical technologies. We develop innovative therapies for the treatment of Alzheimer ́s disease and related neurodegenerative disorders, as well as unique medical technologies that will enable us to detect and monitor treatment effect in patients. This organization form provides stability for continuous evaluation of novel concepts from academic research, but is combined with the overall aim of AlzeCure to commercialize its successful projects. Promising projects will be spun-out as commercial companies, subsidiaries to Alzecure, allowing external partners and investors to buy-in, contribute and collaborate

02/11/2026

A quick update ahead of the BioStock Life Science Summit! 🔬 🚀

We are excited to announce that our co-founder and CEO, Johan Sandin, will be taking the stage to present AlzeCure's latest corporate update and participate in the panel discussion 💫

Johan will discuss our current partnerships, recent achievements, and the path forward as we continue to build momentum and create value for patients and shareholders.

We look forward to connecting with the life science community at the event. See below for further details and registration information.

For more information about the event and tickets, please see the link below: https://biostock.se/event/life-science-summit-2026/

Presentation
📅 November 4 | 10:25–10:40

Panel Discussion: Closing the Deal – Nordic Success Stories
📅 November 4 | 12:10–12:45

Friendly reminder that the Panel and Presentation will be in english

28/10/2026

Exciting news for the rare disease community! 🚀📰🌟

Earlier this month, on October 1, 2026, The Swedish Dental and Pharmaceutical Benefits Agency (TLV) published updated pricing and reimbursement guidelines, including a proposal for a higher willingness to pay for orphan drugs ✨💫

This is an encouraging development for the rare disease community and for patients living with conditions that often have limited treatment options.

At AlzeCure Pharma, we are particularly encouraged by this recognition of the challenges associated with developing therapies for rare diseases. Our drug candidate ACD440 currently holds orphan drug designation from both the FDA and EMA for erythromelalgia, a rare and debilitating condition characterized by severe burning pain.

We welcome TLV's efforts to improve access to innovative treatments and support the development of therapies for patients with high unmet medical needs. ⭐✨🤝

💡Learn more about ACD440: https://www.alzecurepharma.se/en/acd440/

💡Learn more about our orphan drug status for ACD440 in the EU: https://www.alzecurepharma.se/en/pain-project-acd440-granted-orphan-drug-status-in-the-eu/

💡Learn more about our orphan drug status for ACD440 in the US: https://www.alzecurepharma.se/en/alzecures-pain-project-acd440-granted-orphan-drug-status-in-the-us-by-the-fda/

27/10/2026

We are excited to share that AlzeCure Pharma will be joining the panel discussion, "Closing the Deal – Nordic Success Stories," where we will share our experiences from successful partnerships, licensing transactions, and commercial agreements, while discussing the practical realities of dealmaking in the life science industry. 🎤🚀💫

We look forward to sharing our journey, as well as learning from and gaining insights from the experiences of our fellow panelists. We are pleased to take the stage alongside Hansa Biopharma, SAGA Diagnostics, and Askel.🌟

For more information about the event and tickets, please see the link below: https://biostock.se/event/life-science-summit-2026/

Learn more about the panel discussions: https://biostock.se/agenda-biostock-life-science-summit-2026/

27/10/2026

We're pleased to announce that AlzeCure Pharma has been invited to both present and participate in a panel discussion at BioStock Life Science Summit in Lund on November 4.

Our CEO, Martin Jönsson, will provide an update on AlzeCure's journey, discuss our current partnerships with QCell and Eli Lilly, and share insights into the company's future growth and development. Martin will also join the panel discussion, "Closing the Deal – Nordic Success Stories."

For more information about the event and tickets, please see the link below: https://biostock.se/event/life-science-summit-2026/

Presentation
📅 November 4 | 10:25–10:40

Panel Discussion: Closing the Deal – Nordic Success Stories
📅 November 4 | 12:10–12:45

Panel and Presentation will be in english

19/10/2026

We are honored to share that AlzeCure Pharma has been named a finalist in three categories at the European Lifestars Awards 2026🌟

Being recognized alongside so many outstanding companies and individuals in the life science industry is something we are truly grateful for. This is a meaningful acknowledgment of the dedication, collaboration, and hard work that our team brings every day in our mission to develop innovative treatments for patients with difficult-to-treat diseases. 🧠🔬

We would like to extend our sincere thanks to the Lifestars Awards committee for this recognition, and an especially heartfelt thank you to the entire AlzeCure team, whose commitment and passion make achievements like this possible. 💙✨

AlzeCure has been nominated as a finalist in the following categories:
• Licensing Deal of the Year
• Deal of the Year up to €500 million
• Deal of the Year over €500 million

We are proud of this recognition and look forward to celebrating the achievements of the life science community at this year's awards! 🌟💫👏

15/10/2026

Thank you, Redeye, for having us at Neurology Day!

In this presentation, Martin Jönsson discusses the next steps in our collaborations with Eli Lilly and QuantumCell, as well as the broader AlzeCure portfolio, including the Painless platform for pain treatments. 🔬✨

📽️You can watch the presentation via the link below. Martin's presentation begins at 2:00:57:
https://www.redeye.se/events/1145293/redeye-theme-neurology-4

📰To learn more about AlzeCure and our research programs, please visit our website: https://www.alzecurepharma.se/en/

13/10/2026

📸 Thank you, BioJapan 2026!

What an inspiring few days in Yokohama! ✨

We are grateful for another opportunity to be part of BioJapan and connect with pharmaceutical companies, investors, partners, and fellow innovators from across the global life science community.

From productive partnering meetings and insightful discussions to reconnecting with industry colleagues and building new relationships, a BioJapan once again brought together a diverse and engaged global life science community. 🤝 🔬 🌟

We would like to extend a sincere thank you to everyone we had the pleasure of meeting throughout the week, as well as to the many companies and innovators showcasing exciting new technologies and advances across the life science sector. We leave Yokohama with valuable new connections, fresh perspectives, and exciting opportunities for future collaboration.

And if you haven't already, we encourage you to take a look at this BioStock article highlighting reflections from this year's conference and discussing some of the unique characteristics of the Japanese life science market and its growth opportunities.

🔗https://biostock.se/2026/10/report-from-biojapan-nordic-biotech-on-the-long-game-in-japan/

Thank you, BioJapan. Until next time!

13/10/2026

Greeting & Congratulations from Nasdaq to AlzeCure on our major deals

Thanks to Nasdaq for the recognition and for the collaboration and support.nbsp; The deals on USD 3.2 Billion that Nasdaq is referring are the deals we at AlzeCure Pharma did this summer with Eli Lilly and QuantumCell on our Alzheimer’s assets Alzstatin and NeuroRestore. Learn more about the deals here, including about AlzeCure:

⭐Alzstatin (GSM): https://www.alzecurepharma.se/en/alzecure-pharma-enters-into-a-collaboration-and-out-licensing-agreement-with-lilly-for-alzheimers-project/

⭐ NeuroRestore (Trk-PAM): https://www.alzecurepharma.se/en/alzecure-pharma-enters-an-out-licensing-and-collaboration-agreement-with-quantumcell-aps-for-the-neurorestore-acd856-project/

⭐Alzecure: www.alzecurepharma.com https://app.meltwater.com/engage/publish/www.alzecurepharma.com

Thanks again to Nasdaq for the recognition!

08/10/2026

AlzeCure Pharma to present at Aktiespararna in Stockholm on 14 October

At the event, AlzeCure’s CEO Martin Jönsson will provide an update on the company and its project portfolio, including following the recently signed collaboration and outlicensing agreements with Eli Lilly and QuantumCell ApS. Aktiespararna’s analyst Oliver Uutisalo will also take part in the evening, sharing his view on the current state of the stock market.

Presentation time: 18:00 CEST
Venue: Aulan, Medborgarskolan, Hagagatan 23 A, Stockholm, Sweden

The presentation will be held in Swedish. More information and registration are available on Aktiespararna’s website: https://www.aktiespararna.se/aktiviteter/aktiemarknadens-nulage-med-oliver-uutisalo-samt-alzecure-pharma-84493

The presentation will also be available afterwards on AlzeCure’s website: https://www.alzecurepharma.se/en/presentations-and-interviews/

08/10/2026

AlzeCure Pharma presenterar hos Aktiespararna i Stockholm den 14 oktober!

På eventet kommer AlzeCures vd Martin Jönsson ge en uppdatering om bolaget och dess projektportfölj, bland annat efter de nyligen ingångna samarbets- och utlicensieringsavtalen med Eli Lilly och QuantumCell ApS. Under kvällen medverkar även Aktiespararnas analytiker Oliver Uutisalo, som ger sin syn på aktiemarknadens nuläge.

Presentationstid: Onsdagen den 14 oktober 2026 kl. 18.00
Plats: Aulan, Medborgarskolan, Hagagatan 23 A, Stockholm

Presentationen hålls på svenska. Mer information och anmälan finns på Aktiespararnas hemsida: https://www.aktiespararna.se/aktiviteter/aktiemarknadens-nulage-med-oliver-uutisalo-samt-alzecure-pharma-84493

Presentationen kommer även att finnas tillgänglig i efterhand på AlzeCures hemsida: https://www.alzecurepharma.se/sv/presentationer-och-intervjuer/

Adress

Hälsovägen 7
Huddinge
14157

Öppettider

Måndag	08:00 - 17:00
Tisdag	08:00 - 17:00
Onsdag	08:00 - 17:00
Torsdag	08:00 - 17:00
Fredag	08:00 - 17:00

Telefon

+46704979724

Webbplats

http://www.alzecure.org/, https://www.alzecurepharma.se/en/subscribe-media/, https://www.alzecurepharma.se/sv/prenumerer

Aviseringar

Bli först med att veta: vi skickar ett mejl när Alzecure publicerar nyheter och kampanjer. Din e-postadress används inte till något annat, och du kan avsluta prenumerationen när som helst.